Insight

Razan Mohty: Outcomes of patients with IDH1 or 2 mutated AML after alloHCT

Photo from Razan Mohty/X

Aug 17, 2024, 07:45

Razan Mohty: Outcomes of patients with IDH1 or 2 mutated AML after alloHCT

Razan Mohty, Assistant Professor at UAB Medicine, shared a post on X about a recent paper published in BMT journal.

“Isocitrate dehydrogenase (IDH) 1 and 2 mutations predict better outcome in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: a study of the ALWP of the EBMT”

Authors: Razan Mohty et al.

“Check our newly published article on outcomes of patients with IDH1 or 2 mutated AML after alloHCT, a study of the ALWP of The EBMT in BMT journal.

Thank you Abdul-Hamid Bazarbachi, Mohamad Mohty, Myriam Labopin, and all co-authors.”

Source: Razan Mohty/X

More posts by Razan Mohty in OncoDaily.

Abdul-Hamid Bazarbachi Acute Myeloid Leukemia alloHCT ALWP AML BMT journal cancer Mohamad Mohty Myriam Labopin OncoDaily Oncology Razan Mohty The EBMT UAB Medicine

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer